Navigation Links
Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
Date:12/8/2008

icals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to receive regulatory approval for its drug candidates, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

     Contacts:  Jack Lief                             Mary Claire Duch
                President and CEO                     WeissComm Partners
                                                      Media Relat
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
2. Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
3. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
4. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
5. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
6. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
7. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
9. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
10. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
11. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Petersburg, FL (PRWEB) July 30, 2014 Phytceramides are ... how and why in her new book. , Today is the ... Phytoceramides: Anti Aging At Its Best . The book is also ... skin care book, but felt that Phytoceramides were so ... to bring out this focused book now," says Kathy Heshelow, founder ...
(Date:7/29/2014)... Dublin, Ireland (PRWEB) July 30, 2014 ... announced the successful completion of a Phase I trial ... Acid (DGLA). , This study was a randomized, placebo-controlled, ... to assess the safety, pharmacokinetics and effect of food ... confirmed the benign safety profile of DGLA following both ...
(Date:7/29/2014)... July 29, 2014 The Mesothelioma ... the Deadliest Cancer Coalition, led advocacy efforts among ... the newly established Congressional Caucus on the Deadliest Cancers. ... caucus now features the following 20 members: , Rep. Matt ... – May 2, 2014, Rep. Zoe Lofgren (CA-19) – June ...
(Date:7/29/2014)... they have discovered a chemical alteration in a single ... in larger studies, could give doctors a simple blood ... suicide. , The discovery, described online in The ... a gene involved in the function of the brain,s ... turning what might otherwise be an unremarkable reaction to ...
(Date:7/29/2014)... rich in soy may help feminine hearts, but timing ... Menopause , the journal of The North American ... diet of women in Asia, produces the least atherosclerosis. ... Asian migrants to North America, leads to just as ... to soy from a Western diet after menopause helps ...
Breaking Medicine News(10 mins):Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 3Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Soy may help women's hearts if they start early 2
... -- A new study finds that many American children aged ... they ride in cars -- a practice that could prove ... National Highway Traffic Safety Administration survey of nearly 900 drivers. ... 9-year-old passengers use seat belts and more than three-quarters of ...
... FRIDAY, Nov. 18 (HealthDay News) -- Although one in four ... of colon surgery, new research reveals these readmissions -- which ... The most common reason colorectal surgery patients return to ... published in the December issue of the journal Diseases ...
... computing system broke new ground earlier this year when it ... Now, The Scripps Research Institute is hoping to do something ... of the prize money from that tournament: Find a cure ... To that end, Scripps Research and IBM (NYSE: ...
... Nov. 18 (HealthDay News) -- A "tongue-tie" condition in infants ... many cases, an expert says. The condition, also known ... newborns. The most common type is easy to identify and ... tongue indentation at the front of the mouth. Another ...
... HealthDay Reporter , FRIDAY, Nov. 18 (HealthDay News) -- Those ... foods around. U.S. government health experts now encourage ... Weight Watchers, new system assigns no points to nearly all ... But, really, what,s the big deal? Why is it so ...
... rates due to colorectal cancer have declined overall, yet ... suggests that underuse of colonoscopy screening among these groups ... New York City launched a multifaceted campaign to improve ... A new study conducted by researchers at Columbia University,s ...
Cached Medicine News:Health News:Ill-Fitting Children's Seat Belts Common in U.S., Study Finds 2Health News:Colon Surgery Linked to High Readmission Rates 2Health News:Jeopardy! winnings spur IBM and Scripps Research Institute collaboration to fight against malaria 2Health News:Jeopardy! winnings spur IBM and Scripps Research Institute collaboration to fight against malaria 3Health News:Easy-to-Treat Condition Can Disrupt Breast-Feeding 2Health News:For Nutritional Punch, You Can't Beat Plant-Based Foods 2Health News:For Nutritional Punch, You Can't Beat Plant-Based Foods 3Health News:For Nutritional Punch, You Can't Beat Plant-Based Foods 4Health News:Colon cancer screening campaign erases racial, gender gaps in use of colonoscopy 2Health News:Colon cancer screening campaign erases racial, gender gaps in use of colonoscopy 3
(Date:7/30/2014)... California , July 30, 2014 ... technology and CUDA programming expertise to big data, ... markets  eInfochips, a leading engineering R&D ... clients to develop NVIDIA GPU-powered solutions for ... high-performance computing (HPC), industrial , ...
(Date:7/30/2014)... 2014 Die Apex Medical Corporation ... Bereich Atemtherapie- und Druckzonenprodukte, gibt bekannt, dass ... Deutschland anfechten werden. Dieses hat entschieden, dass ... von ResMed verletze. Apex weist darauf hin, ... verschiedene Patente von ResMed Anfechtungen wegen Nichtigkeit ...
(Date:7/29/2014)... Israel , July 30, 2014  Immune ... Stockholm : "IMNP."; "Immune" or "the ... of patients for a Phase II proof of concept ... in the treatment of moderate to severe bullous pemphigoid. ... receive two bertilimumab infusions, at a dose of 10 ...
Breaking Medicine Technology:eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5
... is little evidence to support the use of atypical ... approved purposes, even though many clinicians continue to commonly ... to a new report from the U.S. Department of ... and Quality (AHRQ). An article based on information in ...
... The Houston Business Journal recently announced that eCardio Diagnostics ... Fast 100, which included a distinguished list of 100 of ... eCardio was ranked No. 17 with a two-year growth ... to receive this prestigious award. "There were so ...
Cached Medicine Technology:"Off-Label" Use of Antipsychotic Drugs for Some Conditions Not Supported By Evidence 2eCardio Among Honorees of the Houston Business Journal's Fast 100 List for Second Consecutive Year 2
For use with E5381 600 Circling Band (40 style). 2.2 mm diameter, 28.5 mm long....
Used with Double Tantalum Clip (250 style) E5381 852. Overall length: 7.0 mm....
Concave inner surface to conform to globe. Used in conjunction with the E5381 700 Circling Band (240 style). Indications: wide scleral bed. Outside diameter 31.7 mm....
Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Medicine Products: